शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

PVPNSEPVP Ventures Limited· RealtyHighNeutral
Announced Wed, 20 Aug, 2025 · 22:34 IST

PVP Ventures Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Emphasis of matterRelated-party transactionsResults View source PDFExplain this filing

PVP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-5.2%Reaction day
₹21.19
prior close
₹20.50
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-5.5% vs market
Residential Commercial Projects peers, median of 60sector+0.4%-5.6% vs sector

On the reaction day the stock moved 5.5 pts less than Nifty Microcap 250 and 5.6 pts less than its Residential Commercial Projects peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.4
10m
+2.0
15m
+2.4
30m
+0.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-5.2+0.3-5.5+0.4-5.6
Next day
-1.0-0.3-0.8-0.5-0.6
2d
-4.9-0.4-4.4+0.0-4.9
3d
-0.9-2.1+1.2-0.9-0.0
4d
-1.7-2.8+1.1-2.5+0.7
5d
-1.1-3.0+1.8-3.5+2.3
1w
+1.4-0.9+2.3-1.8+3.2
15d
+43.6+0.3+43.3-1.0+44.7
1m
+35.0+1.6+33.4+2.0+33.0
2m
+39.1+0.6+38.5+0.2+38.9
3m
+78.8-2.8+81.6-4.1+82.9
UpDownMarket · Nifty Microcap 250Sector · Residential Commercial Projects peers, median of 60Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

PVP Ventures submitted Q1 FY26 results with standalone revenue from operations of ₹919.28 lakhs (vs nil in Q1 FY25) and total income of ₹1,275.85 lakhs, swinging to a net profit of ₹78.19 lakhs from a loss of ₹138.64 lakhs year-on-year. However, finance costs surged to ₹805.75 lakhs (vs ₹110.63 lakhs) due to amortization of NCD issuance costs after the company allotted ₹15,000 lakhs of secured NCDs in April 2025. The auditor flagged multiple emphasis-of-matter items: SEBI summons to the company, CEO and MD over past related-party transactions with erstwhile subsidiaries; a ₹21,843.49 lakh interest-free loan to related party NCCPL whose underlying land is under ED/SEBI attachment; a ₹2,800 lakh receivable from PHML (related party with negative net worth and continuing losses); pending GST, income tax, stamp duty and SEBI appeals; and a ₹669.69 lakh exceptional impairment on the HHT acquisition. The company also completed acquisitions of Optimus Oncology (56%) and Biohygea Global/Medilabs (52%) during the quarter.

Likely market impact

Shareholders should weigh the SEBI investigation, large unprovided related-party exposures (over ₹24,600 lakhs to NCCPL and PHML combined), negative other equity of ₹(4,953.95) lakhs, and very weak debt service (0.14) and interest coverage (0.18) ratios, all of which signal elevated risk despite the return to quarterly profit.

By the numbersConsolidated · Q1 FY26

The company's XBRL figures for this quarter look filed in the wrong unit: revenue reads ₹17.21 Cr against ₹2.52 Cr a year ago, about 7× larger. A move that size is almost always a wrong unit, not a business, so nothing is computed from these figures and no number-based tags are set; the read above is the AI's, from the document.